Voyageur Pharmaceuticals Ltd. (TSXV:VM) (OTC:VYYRF) (the "Company" or "Voyageur") is pleased to announce that it has received approval from Health Canada for its second product, HDXBa. HDXBa is a barium radiographic contrast powder for suspension that is specifically formulated for Fluoroscopy barium X-Ray procedures and can also be used for CT Scans. This approval authorizes the sale of HDXBa for use in radiology procedures in Canada. HDXBa is specifically designed for X-Ray procedures of the entire upper and lower GI tract, including the stomach and duodenum for use in both adults and pediatric patients.
This represents the second Health Canada licence approval for Voyageur, which has three additional barium radiographic contrast products currently under review by Health Canada, with approvals expected forthcoming.
“This approval is another key milestone to allow our company to transition to manufacturing and production” reports Brent Willis, Voyageur’s CEO.
Voyageur has a strategic plan to advance through the start-up phase of formulating, final testing of product and then manufacturing. This is expected to lead to full production manufacturing, sales and distribution of barium contrast products nationally in the near term.
About Voyageur
Voyageur Pharmaceuticals Ltd. is Canadian public company listed on the TSX Venture Exchange under the trading symbol VM. Voyageur is focused on the development of barite and iodine, Active Pharmaceutical Ingredient (API) minerals. The near-term focus is developing barium and iodine radio-contrast pharmaceutical products.
Voyageur’s goal is to initially generate the positive cash flow from operations using third party GMP pharmaceutical manufacturers in Canada and in India. Ultimately, Voyageur has plans to build all the required infrastructure to become 100% self-sufficient with all manufacturing.
Voyageur owns a 100% interest in three barium sulfate (barite) projects including two properties suitable in grade for the industrial barite marketplace, with interests in a high-grade iodine, lithium & bromine brine project located in Utah, USA.
Voyageur is moving forward with its business plan of becoming the only fully-integrated company in the radiocontrast medical field, by controlling all primary input costs under the motto of:
"From the Earth to the Bottle"
www.voyageurpharmaceuticals.ca
For Further Media Information or to set up an interview, please contact:
Brent Willis
President & CEO
E This email address is being protected from spambots. You need JavaScript enabled to view it.
Ron Love
CFO
T 403.818.6086
E This email address is being protected from spambots. You need JavaScript enabled to view it.
Forward Looking Information
This news release may contain certain forward-looking information and statements, including without limitation, statements pertaining to timing for manufacturing and sales of HDXBa and the Company's ability to obtain necessary approvals from Health Canada for the four additional barium radiographic contrast products. All statements included herein, other than statements of historical fact, are forward-looking information and such information involves various risks and uncertainties. There can be no assurance that such information will prove to be accurate, and actual results and future events could differ materially from those anticipated in such information. A description of assumptions used to develop such forward-looking information and a description of risk factors that may cause actual results to differ materially from forward-looking information can be found in the Company's disclosure documents on the SEDAR website at www.sedar.com. Voyageur does not undertake to update any forward-looking information except in accordance with applicable securities laws.
Reader Advisory
Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this news release.
